NAVB Navidea Biopharmaceuticals, Inc

-0.0169  -4%
Previous Close 0.46
Open 0.45
Price To book 3.41
Market Cap 71.13M
Shares 160,376,000
Volume 343,321
Short Ratio 11.76
Av. Daily Volume 772,276

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved March 13, 2013.
Lymphatic-tissue tracing agent
Phase 3 - seeking partner to continue development
Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Approved June 13, 2014.
Head and Neck Cancer
Phase 2 enrolment commenced February 2016
Uterine Cervical Neoplasms
Phase 1/2 initiated February 2017.
Rheumatoid arthritis

Latest News

  1. Navidea Biopharmaceuticals, Inc. :NAVB-US: Earnings Analysis: Q1, 2017 By the Numbers : May 26, 2017
  2. Edited Transcript of NAVB earnings conference call or presentation 10-May-17 12:00pm GMT
  3. Navidea pays former CEO $618,000 after losing arbitration over his firing
  4. Navidea posts 1Q profit
  5. Navidea Biopharmaceuticals Reports First Quarter 2017 Financial Results
  6. Navidea Biopharmaceuticals Invited to Present Data at Two Major Upcoming Conferences
  7. ETFs with exposure to Navidea Biopharmaceuticals, Inc. : April 19, 2017
  8. Navidea Biopharmaceuticals, Inc. :NAVB-US: Earnings Analysis: Q4, 2016 By the Numbers : April 4, 2017
  9. Navidea halved losses in 2016, projects positive cash flow in 2017
  10. Navidea reports 4Q loss
  11. Navidea Provides Corporate Update and Reports Full Year 2016 Results
  12. Why Navidea can recover no more than $12M if it wins against ex-lender in court
  13. Navidea closes Lymphoseek sale to Cardinal Health; lender CRG accepts loan payment, drops liens
  14. Navidea Completes Sale of North American Rights of Lymphoseek® to Cardinal Health
  15. Cardinal Health helps Navidea settle lender's payoff – for now
  16. Navidea to Hold Conference Call to Provide Investor Update on Status of Ongoing Corporate Events
  17. Navidea to Present at Upcoming Investor Conference
  18. ETFs with exposure to Navidea Biopharmaceuticals, Inc. : December 29, 2016